电邮这篇文章 Analgesic activity of the low molecular weight neurotrophin-3 dipeptide mimetic GTS-301
- 作者: Kolik L.G.1, Konstantinopolsky M.A.1, Sazonova N.M.1, Durnev A.D.1, Gudasheva T.A.1
-
隶属关系:
- FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
- 期: 卷 520, 编号 1 (2025)
- 页面: 100-103
- 栏目: Articles
- URL: https://ruspoj.com/2686-7389/article/view/682051
- DOI: https://doi.org/10.31857/S2686738925010166
- EDN: https://elibrary.ru/tcgjna
- ID: 682051
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
It was previously shown that the original dipeptide mimetic of the 4th loop neurotrophin-3 (NT-3) hexamethylenediamide bis-(N-monosuccinyl-L-asparaginyl-L-asparagine) (GTS-301), like full-size neurotrophin, predominantly activates the tyrosine kinase receptor TrkC and has a neuroprotective effect in vitro at concentrations of 10-5-10-12 M, as well as after systemic administration on rodents – antidiabetic (0.1 and 0.5 mg/kg) and antidepressant (5 and 10 mg/kg) effects. In this work, the analgesic properties of GTS-301 were identified, which were manifested in the dose range of 0.01-10 mg/kg after acute intraperitoneal injection to rats in the “tail flick” test. Dipeptide GTS-301 increased the threshold of pain response by 20-30% and the effect persisted for at least 24 hours after administration.
全文:
作者简介
L. Kolik
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
编辑信件的主要联系方式.
Email: kolik_lg@academpharm.ru
俄罗斯联邦, Moscow
M. Konstantinopolsky
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
俄罗斯联邦, Moscow
N. Sazonova
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
俄罗斯联邦, Moscow
A. Durnev
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Сorresponding Мember of the RAS
俄罗斯联邦, MoscowT. Gudasheva
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Сorresponding Мember of the RAS
俄罗斯联邦, Moscow参考
- Hohn A., Leibrock J., Bailey K., et al. // Nature. 1990. V. 344. P. 339–341.
- Rosenthal A., Goeddel D.V., Nguyen T., et al. // Neuron. 1990. V. 4. P. 767–773.
- Siuciak J. A., Altar A., Wiegand S. J., et al. // Brain Res. 1994. V. 633, № 1–2. P. 326–330.
- Malcangio M., Garrett N. E., Cruwys S., et al. // J. Neurosci. 1997. V. 17. № 21. P. 8459.
- Watanabe M., Endo Y., Kimoto K., et al. // Neurosci. Lett. 2000. V. 1–2. № 282. P. 61–64.
- Wilson-Gerwing T.D., Dmyterko M.V., Zochodne D.W., et al. // J. Neurosci. 2005. V. 25. № 3. P. 758–767.
- Gudasheva T.A., Povarnina P.Y., Tarasiuk A.V., et al. // Med Res Rev. 2021. V. 41. № 5. P. 2746-2774. doi: 10.1002/med.21721.
- Гудашева Т.А., Сазонова Н.М., Тарасюк А.В., и др. // ДАН. 2022. Т. 505. № 1. С. 303-309.
- Ягубова С.С., Чернышевская М.А., Островская Р.У., и др. // ДАН. 2023. Т. 512.
- Hardy J.D., Wolff H.G. and Goodell H. // J Clin Invest. 1940. V. 19. P.649–657.
- Bannon A.W., Malmberg A.B. // Curr Protoc Neurosci. 2007. Chapter 8:Unit 8.9.
- Douglas D.K. and Carstens E. // J Neurophysiol. 1997. V. 77. P. 611–620.
- Maisonpierre P.C., Belluscio L., Friedman B., et al. // Neuron. 1990. V. 5. P. 501–509.
- Ernfors P., Rosario C.M., Merlio J.P., et al. // Brain Res. Mol. Brain Res. 1993. V.17. P. 217–226.
- Гудашева Т.А., Константинопольский М.А., Тарасюк А.В., и др. // ДАН. 2019. Т. 485. № 3. С. 366–369.
- Helgren M.E, Cliffer K.D., Torrento K., et al. // J. Neurosci. 1997. V. 17. P. 372–382.
- Sahenk Z., Nagaraja H.N., McCracken B.S., et al. // Neurology. 2005. V. 65. P. 681–689.
- Степанова О.В., Воронова А.Д., Чадин А.В., и др. // Клеточные технологии в биологии и медицине. 2022. Т. 1. С. 3–8.
补充文件
